106 results about "Active tuberculosis" patented technology

The invention discloses a pulmonary tuberculosis image classification and recognition system based on feature aggregation and focus area perception, and the system comprises the steps: carrying out the local and global feature extraction and fusion of a pulmonary tuberculosis image through a feature extraction subsystem; the method comprises the following steps: constructing a graph structure of fusion features through a pulmonary tuberculosis classification subsystem based on focus area perception, dynamically aggregating node information, realizing three classifications of health, tuberculosis and disease but non-tuberculosis in a first stage, and carrying out active tuberculosis and old tuberculosis subdivision in a second stage on a pulmonary tuberculosis image in combination with focus structure features; through an unbalanced data set processing subsystem based on characteristic aggregation and dynamic data amplification, under-sampling is carried out on the characteristic that active tuberculosis data samples are large by adopting a characteristic aggregation technology, and resampling is carried out on old tuberculosis with few data samples by implementing a dynamic data amplification strategy; and key information learned from active tuberculosis categories is reserved through a knowledge distillation mechanism, so that more accurate focus recognition and classification are realized.

The invention discloses an active / inactive pulmonary tuberculosis recognition system based on an improved 3D network, and the system comprises an image feature obtaining module which is used for obtaining pulmonary tuberculosis CT chest image features; the data preprocessing module is used for carrying out data preprocessing on the obtained pulmonary tuberculosis CT chest image features; the image segmentation module is used for segmenting the preprocessed pulmonary tuberculosis CT chest image features to obtain pulmonary parenchyma image features, and an adopted segmentation model is a 3D ResUNet segmentation model; the image classification and recognition module is used for performing prediction and classification on the lung parenchyma image features after image segmentation; wherein the adopted image classification model is a 3D ResUNet50 classification model, and the 3D ResUNet50 classification model is combined with a multi-scale attention module to obtain image output features; then, image output features are processed by adopting grouping convolution and channel shuffling, the types of active and inactive pulmonary tuberculosis are predicted, and confidence scores of the model are generated; the CT image classification accuracy of the model can be improved.

The invention belongs to the field of biological medicine, and relates to a tuberculosis molecular marker combination and application thereof. Specifically, the invention relates to a molecular marker combination, which comprises (A) nucleic acid for coding GLRX protein, and one or more of nucleic acid for coding FCGR1A protein, nucleic acid for coding IFITM1 protein and nucleic acid for coding UBE2L6 protein; or (B) a GLRX protein, and one or more selected from the group consisting of an FCGR1A protein, an IFITM1 protein, and a UBE2L6 protein. The molecular marker combination can effectively diagnose the active tuberculosis or effectively distinguish the active tuberculosis from latent tuberculosis infection and normal control, and has high sensitivity and specificity.

The invention belongs to the technical field of biology, and particularly relates to a biomarker for differential diagnosis of pulmonary tuberculosis in different stages. The marker provided by the invention is an SCF expression level, and active tuberculosis patients can be screened from healthy people and tuberculosis patients; patients in two different stages, namely an incubation stage and an active stage, can be screened from pulmonary tuberculosis patients. And when the SCF protein expression level is less than or equal to 9.712 pg / ml, judging that the subject is an active tuberculosis patient. In the screening group, LTBI vs TB has an area under an ROC curve of 0.9006, a sensitivity of 88.46% and a specificity of 83.33%. In a verification group, LTBI vs TB, the area under an ROC curve is 0.9432, the sensitivity is 90.91%, and the specificity is 100.00%. The marker detection method is convenient to operate, simple in process, low in cost and good in sensitivity and specificity, and can be put into use in the market.

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.

The invention discloses a cytokine combination for distinguishing active tuberculosis from latent tuberculosis infection. The invention also provides an application of the cell factor combination in establishing a machine learning model for distinguishing active tuberculosis and latent tuberculosis infection, and provides a machine learning model for distinguishing active tuberculosis and latent tuberculosis infection based on the application. And inputting the expression level of each cytokine in the cytokine combination of a sample to be detected into the machine learning model as an input variable, and judging whether the sample is an active tuberculosis sample or a tuberculosis latent infection sample based on an output result of the machine learning model. The cell factor combination is combined with the machine learning model to distinguish the active tuberculosis and the latent tuberculosis infection, the specificity reaches 66.67%-83.33%, the sensitivity reaches 92.86%-100%, the accuracy reaches 90%, and the method can be used for accurately distinguishing the active tuberculosis and the latent tuberculosis infection.

The invention discloses an active tuberculosis diagnosis method based on proteomics and metabonomics. The method comprises the following steps: collecting a serum sample of a suspected active tuberculosis patient; detecting specific proteins in the serum sample by using a proteomics technology; detecting specific amino acids in the serum sample by using a metabonomics technology; carrying out standardization treatment on the obtained protein, amino acid and bile acid data; establishing a diagnosis model by using a machine learning algorithm; inputting data of a to-be-diagnosed sample into the model, and calculating a probability value of the to-be-diagnosed sample suffering from active tuberculosis; according to a preset threshold value, whether the sample provider suffers from the active tuberculosis or not is judged. By comprehensively analyzing multiple omics data, the sensitivity and specificity of diagnosis are greatly improved; by utilizing a machine learning algorithm, the disease risk can be objectively and quantitatively evaluated, and human misjudgment is reduced; the detection process is simple and fast, the sample demand is small, and clinical popularization and application are facilitated.

The invention belongs to the technical field of biology, and particularly relates to a group of markers for diagnosing active tuberculosis and application. The biomarker is easy and convenient to sample, only peripheral blood needs to be taken for detection, and the result reporting speed is high. The biomarker disclosed by the invention is high in accuracy: when a subject's working characteristic curve (ROC) analysis shows that when GCH1, GK, MTHFD2 and SLC7A6 are combined, it can be known through database screening that the ROC for diagnosing active tuberculosis patients in TB patients, HC control and LTBI patients is 0.906, the specificity is 93.9, and the sensitivity is 85.7; clinical tests prove that the ROC of active tuberculosis patients in TB patients, HC control and LTBI patients is 0.942, the specificity is 90.9, and the sensitivity is 85.7.

An exemplary embodiment of the present disclosure provides a composition for identifying a presence of tuberculosis in a subject. The composition comprises a molecule of interest configured to bind with a target molecule in a biological sample; a probe molecule configured to bind with the target molecule; and a metal particle configured to bind with the probe molecule. Another aspect of the present disclosure provides a method of diagnosing diagnosing tuberculosis in a subject. The method comprises combining the composition of the present disclosure with a sample solution comprising the biological sample to form a testing sample, imaging the testing sample, and determining, based on an image of the testing sample, whether the biological sample comprises an active tuberculosis infection.

The invention provides a risk marker for active tuberculosis screening and application thereof. Specifically, the invention provides application of a gene, mRNA, cDNA and protein of a marker for the occurrence risk of active tuberculosis or a detection reagent thereof, and the gene, the mRNA, the cDNA and the protein are used for preparing the detection reagent or the kit for judging the occurrence risk. Researches show that the active tuberculosis risk marker can be used as a marker for judging the occurrence of active tuberculosis, and has high sensitivity and specificity.

Disclosed are an mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one early-secreted antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof; PE / PPE family antigen WAG22 of Mycobacterium tuberculosis or an immunologically active fragment thereof; and at least one latent-related antigen of Mycobacterium tuberculosis or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which may serve as a prophylactic vaccine for preventing latent activation or as a therapeutic drug for treating active tuberculosis, exhibiting a significant inhibitory effect on Mycobacterium tuberculosis.

The invention provides an mRNA (messenger ribonucleic acid) pharmaceutical composition for preventing and treating tuberculosis and application of the mRNA pharmaceutical composition. The mRNA pharmaceutical composition for preventing and treating tuberculosis comprises mRNA molecules for coding mycobacterium tuberculosis antigens and pharmaceutically acceptable auxiliary materials, the mycobacterium tuberculosis antigen comprises the following antigen components: at least one mycobacterium tuberculosis early secretion antigen or an immunocompetence fragment thereof; a mycobacterium tuberculosis PE / PPE family antigen Rv3872 or an immunocompetence fragment thereof; and at least one mycobacterium tuberculosis latent associated antigen or an immunocompetent fragment thereof; the mRNA pharmaceutical composition does not include or further includes an mRNA molecule encoding a cytokine. The pharmaceutical composition provided by the invention is used for preparing tuberculosis vaccines, can be used as a prophylactic vaccine for preventing latent activation, can also be used as a therapeutic drug for treating active tuberculosis, and has a remarkable inhibition effect on mycobacterium tuberculosis.

The present invention discloses a kit for diagnosing active tuberculosis. The kit includes a substance for detecting IFIT3 protein. Compared with healthy people and latent tuberculosis infected people, the expression of IFIT3 gene in PBMCs of active tuberculosis patients is significantly increased; the expression of IFIT3 gene can be used to distinguish active tuberculosis patients from latent tuberculosis infected people; the expression of IFIT3 gene can be used to distinguish active tuberculosis patients from healthy people. Therefore, IFIT3 protein and / or IFIT3 gene can be used as a marker to diagnose active tuberculosis. The present invention has great application value.

The present application relates to the technical field of diagnostic markers, in particular to a marker combination and its application in diagnosing active tuberculosis and distinguishing between latent tuberculosis infection and active tuberculosis. The lectin combination provided by the present application can be used as a marker for ATB diagnosis and distinguishing between LTBI and ATB, and has high specificity and sensitivity. The lectin combination provided by the present application in combination with detection of specific antibodies of mycobacterium tuberculosis antigens can further improve the diagnostic effect. The marker and its detection products provided by the present application have good application potential in ATB diagnosis and distinguishing between LTBI and ATB, and are expected to overcome the limitations of existing diagnostic techniques, improve the diagnostic accuracy and sensitivity of tuberculosis, and provide new ideas and technical means for early detection, precise treatment and effective prevention and control of tuberculosis.

The present invention relates to the use of a therapeutic agent based on cell wall fragments of a virulent strain of Mycobacterium tuberculosis-complex for the preparation of a drug for the treatment of patients with active tuberculosis.

The invention discloses a plasma exosome marker of tuberculosis (TB) and application of the plasma exosome marker, and belongs to the field of biomedical diagnosis, the plasma exosome marker comprises hsa-miR-451a, hsa-miR-1908-5p and hsa-miR-1268b, the expression of hsa-miR-451a in the plasma exosome of an active TB patient is up-regulated, and the expression of the hsa-miR-451a and the expression of the hsa-miR-451a and the expression of the hsa-miR-1908-5p are down-regulated. The expression levels of the markers are detected by using a droplet digital PCR technology, and a multinomial logistic regression diagnosis model is constructed based on a detection result. Experiments prove that when the three miRNA combinations are used for distinguishing active tuberculosis from healthy control (HC), the area (AUC) under a working characteristic curve of a subject reaches 0.970; when latent tuberculosis infection (LTBI) is distinguished from a healthy control, AUC is 0.971; and when the secondary miRNA combination of the hsa-miR-451a and the hsa-miR-1268b is used for distinguishing the asymptomatic tuberculosis (aTB) from the healthy control, the AUC is 0.880. The TB early diagnosis accuracy is remarkably improved, the non-invasive advantage is achieved, wide application prospects are achieved in the aspects of preparation of diagnostic reagents and kits, clinical diagnosis, disease monitoring and the like, and global tuberculosis prevention and control work is powerfully promoted.

The invention relates to the technical field of diagnostic markers, in particular to a marker combination for diagnosing active tuberculosis and distinguishing latent tuberculosis infection and active tuberculosis and application of the marker combination. The lectin combination which can be used for ATB diagnosis and can distinguish LTBI and ATB is obtained by detecting the IgG glycosylation condition in the onset process of tuberculosis, and the lectin combination can be used as a marker for ATB diagnosis and distinguishing LTBI and ATB, and has high specificity and sensitivity; a new thought and method are provided for distinguishing different stages of tuberculosis and early accurate diagnosis of ATB, and the lectin combination is combined with the tuberculosis antigen to detect the specific antibody, so that the diagnosis effect can be further improved. The marker combination and the detection product thereof provided by the invention have relatively good application potential in ATB diagnosis and LTBI and ATB distinguishing.

The invention relates to the technical field of pulmonary tuberculosis image classification methods, in particular to a training method of an active pulmonary tuberculosis detection model and a detection device and equipment.The method comprises the steps that front-position CXR data and lateral-position CXR data of a to-be-detected object are obtained, the CXR data in a preset proportion are marked, the marked CXR data form a first training data set, and the first training data set is used for training the to-be-detected object; the rest forms a second training data set; training a self-supervised model based on the second training data set to determine an encoder module, the encoder module being used for extracting a feature vector of an input image; training a supervised learning model based on the first training data set to generate the active tuberculosis detection model, the supervised learning model comprising a feature extraction module and a prediction module, the feature extraction module having the same network structure as the encoder module and being initialized by the encoder module; the accuracy of the active tuberculosis automatic screening method can be improved.

The present invention relates to an isolated antibody that specifically binds to human interferon-γ (IFN-γ) and its applications in diagnosing active tuberculosis infection. The antibody described herein exhibits high specificity and affinity towards IFN-γ, enabling accurate detection of IFN-γ in extrapulmonary fluid samples. The present invention also relates to the use of the antibody in in vitro methods of diagnosis of active TB and to an immunoassay device which incorporates the antibody.

The invention belongs to the technical field of tuberculosis detection, and provides a microRNA combination for bimodal differentiation of tuberculosis infection, a kit and a detection system. Nine specific microRNAs and one specific internal reference microRNA are taken as markers, the microRNAs in plasma are rapidly released by adopting a direct splitting method, the relative expression quantity of the markers is synchronously detected in combination with a tailing method reverse transcription technology, a four-group primer grouping amplification technology and a fluorescent PCR technology, a comprehensive risk value is calculated through a built-in algorithm, and latent tuberculosis infection, active infection and a negative state are synchronously distinguished. According to the invention, sputum samples are not needed, the detection is rapid and efficient, the detection sensitivity and specificity of active tuberculosis infection reach 92%, the detection sensitivity and specificity of latent tuberculosis infection reach 93%, the detection specificity reaches 90%, the operation is convenient, and the application range is wide.

The application relates to an active pulmonary tuberculosis marker and application thereof, the active pulmonary tuberculosis marker is PCBP1, the expression of the PCBP1 in peripheral blood mononuclear cells of an active pulmonary tuberculosis patient is obviously down-regulated, the down-regulated PCBP1 has certain significance for diagnosis of the active pulmonary tuberculosis patient. Moreover, the expression amount of the PCBP1 in the APTB patient is detected by using an RT-qPCR and western blot method, the disease can be diagnosed, and then the active pulmonary tuberculosis diagnosis reagent can be prepared. The application discloses that the PCBP1 can be used as the active pulmonary tuberculosis marker for the first time, and provides a new direction for clinical diagnosis of the active pulmonary tuberculosis.

The present invention relates to an mRNA pharmaceutical composition for the prevention and treatment of tuberculosis and uses thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient; the Mycobacterium tuberculosis antigen comprises the following antigenic components: at least one Mycobacterium tuberculosis early secreted antigen or an immunologically active fragment thereof; Mycobacterium tuberculosis PE / PPE family antigen WAG22 or an immunologically active fragment thereof; and at least one Mycobacterium tuberculosis latency-associated antigen or an immunologically active fragment thereof; the mRNA pharmaceutical composition either comprises no mRNA molecules encoding cytokines or further comprises cytokine-encoding mRNA molecules; The pharmaceutical composition described herein is for use in the preparation of a tuberculosis vaccine. The vaccine may be used as a prophylactic vaccine to prevent reactivation of latent infection, and may also be used as a therapeutic agent for treating diseases associated with active tuberculosis. The vaccine exhibits significant inhibitory activity against Mycobacterium tuberculosis.

The invention discloses a three-gene combination, a primer probe set and a system for qPCR (quantitative polymerase chain reaction) rapid screening of tuberculosis progression risk and application of the three-gene combination, the primer probe set and the system. The method comprises the following steps: firstly, screening out candidate genes APOL1, C1QC and SOCS1 which are stable across time windows and have high prediction performance; then a three-gene combination scoring you model (PRI3) composed of APOL1, C1QC and SOCS1 is constructed and used for predicting the risk that a latent tuberculosis infected individual progresses into active tuberculosis within a set time window; the method comprises the following steps of: firstly, selecting a reference model (RISK6, Sweeney3, Gliddon4 and BATF2), then performing performance verification in an independent verification queue, and comparing with the existing reference model (RISK6, Sweeney3, Gliddon4 and BATF2), and the result shows that the scoring model disclosed by the invention can keep stable performance in adult population and multiple time windows (such as 0-6 months, 0-12 months and 0-24 months). The scheme of the invention is suitable for crowd screening, disease early warning and individualized intervention decision.

An mRNA pharmaceutical composition for preventing and treating tuberculosis and use thereof. The mRNA pharmaceutical composition comprises: an mRNA molecule encoding a Mycobacterium tuberculosis antigen, and a pharmaceutically acceptable excipient. The Mycobacterium tuberculosis antigen comprises the following antigen components: at least one Mycobacterium tuberculosis early-secreted antigen or an immunologically active fragment thereof; Mycobacterium tuberculosis PE / PPE family antigen Rv3872 or an immunologically active fragment thereof; and at least one Mycobacterium tuberculosis latency-associated antigen or an immunologically active fragment thereof. The mRNA pharmaceutical composition does not comprise or further comprises an mRNA molecule encoding a cytokine. The pharmaceutical composition is used for preparing a tuberculosis vaccine, which can be used not only as a prophylactic vaccine for preventing latency activation, but also as a therapeutic drug for treating active tuberculosis, and has a significant inhibitory effect on Mycobacterium tuberculosis.

The invention relates to a T cell intracellular factor composition and application thereof, the T cell intracellular factor composition is selected from multiple of CCL3, CCL4, IFN gamma and TNFa, and the expression levels of the CCL3, the CCL4, the IFN gamma and the TNFa in peripheral blood of active tuberculosis patients are obviously different. As the expression levels in the peripheral blood of the active tuberculosis patient are obviously different, different stages and health states of tuberculosis can be accurately distinguished, the accuracy and specificity of diagnosis are obviously improved, and a reliable basis is provided for clinical diagnosis.

The present application relates to an isolated antibody that specifically binds to human interferon-γ (IFN-γ) and its applications in diagnosing active tuberculosis infection. The antibody described herein exhibits high specificity and affinity towards IFN-γ, enabling accurate detection of IFN-γ in extrapulmonary fluid samples. The present application also relates to the use of the antibody in in vitro methods of diagnosis of active TB and to an immunoassay device which incorporates the antibody.

The invention relates to a tuberculosis antigen specific host biomarker for detecting tuberculosis infection and a kit, and belongs to the field of biological medicines. The biomarker comprises IFN gamma, CXCL10, IL-2, IL-3, GBP6, ULBP2, CXCL11, ATP13A3, RHOV, ATP2B1, IL-22 and MMP1 (Metallocin Protein Protein 1). According to the present invention, the specific RD1 region antigen or peptide pool from mycobacterium tuberculosis and the specific RD2 region antigen or peptide pool from mycobacterium tuberculosis are jointly used as the antigen irritants to stimulate peripheral whole blood or peripheral blood mononuclear cells (PBMCs) of an individual to be detected, and then the expression quantity change of the host biomarker before and after the stimulation is detected; the kit can effectively distinguish tuberculosis infected patients from non-tuberculosis infected individuals, can identify and diagnose active tuberculosis and latent tuberculosis infected patients, solves the defects of insufficient sensitivity and limited specificity of the existing diagnostic technology, and has high diagnostic efficiency.

The present invention discloses an antibody combination for detecting mycobacterial lipoarabinomannan, its application, and a kit, relating to the field of biological detection. The inventors of this application screened and identified various sample types, identifying capture antibodies suitable for LAM antigen capture and detection antibodies suitable for LAM antigen detection. This resulted in a superior antibody combination for LAM antigen detection, which exhibits high sensitivity and specificity and can be used to detect LAM antigens in purified LAM, standard strains of Mycobacterium tuberculosis, clinical isolates, pleural effusions, plasma, and other bodily fluids. This provides a new antibody combination and method for LAM antigen detection, as well as a new method and kit for the auxiliary diagnosis of active tuberculosis.

The invention discloses an application of an extracellular vesicle B and T lymphocyte weakening factor in active tuberculosis diagnosis, relates to the technical field of biomedicine, and particularly discloses an application of the extracellular vesicle B and T lymphocyte weakening factor as a diagnostic marker of active tuberculosis in preparation of an active tuberculosis diagnostic product. The extracellular vesicle B and T lymphocyte weakening factor can effectively distinguish active tuberculosis patients from healthy people, tuberculosis latent infection patients and lung cancer patients, can be used for diagnosing active tuberculosis, and has high sensitivity and specificity.

The invention provides an mRNA (messenger ribonucleic acid) pharmaceutical composition for preventing and treating tuberculosis and application of the mRNA pharmaceutical composition. The mRNA pharmaceutical composition for preventing and treating tuberculosis comprises mRNA molecules for coding mycobacterium tuberculosis antigens and pharmaceutically acceptable auxiliary materials, the mycobacterium tuberculosis antigen comprises the following antigen components: at least one mycobacterium tuberculosis early secretion antigen or an immunocompetence fragment thereof; at least one Mycobacterium tuberculosis PE / PPE family antigen or an immunologically active fragment thereof; and at least one mycobacterium tuberculosis latent associated antigen or an immunocompetent fragment thereof; the mRNA pharmaceutical composition does not include or further includes an mRNA molecule encoding a cytokine. The pharmaceutical composition provided by the invention is used for preparing tuberculosis vaccines, can be used as a prophylactic vaccine for preventing latent activation, can also be used as a therapeutic drug for treating active tuberculosis, and has a remarkable inhibition effect on mycobacterium tuberculosis.